Probe the Immune Repertoire for Rare Clones: A New Path to Antibodies, Vaccines, and Therapeutic Candidates

Learn how high-resolution TCR and BCR sequencing and advanced data analytics uncover therapeutic immune responses and accelerate infectious disease and vaccine development.

Key Takeaways:

• The adaptive immune system generates rare, highly specific clonotypes during infection and vaccination that hold direct therapeutic potential, yet most immune profiling assays cannot reliably detect or characterize them.
• TCR and BCR sequencing enable discovery, quantification, and longitudinal tracking of rare antigen-specific clones that define protective immunity.
• Translating repertoire data into therapeutic candidates requires single-cell pairing that links clonotype identity to function, connecting sequence to mechanism.
• Combined high-sensitivity bulk AIRR sequencing, single-cell immune profiling, and advanced data analytics form a complete pipeline for infectious disease research, vaccine evaluation, and monoclonal antibody discovery.

Finding Therapeutic Candidates Within the Immune System

The most powerful vaccine therapies for infectious disease may already exist inside the immune system. Each infection or vaccination leaves a molecular record of immune adaptation, encoded in rare T cell and B cell clones capable of neutralizing pathogens, blocking transmission, or conferring long-term protection. The challenge, however, is finding them, characterizing them, and translating them into therapies.

This is where immune repertoire sequencing transforms infectious disease research from population-level monitoring into precision therapeutic discovery. High-resolution TCR sequencing and BCR sequencing give researchers the depth needed to resolve the rare, clinically meaningful clonotypes that drive protection, and to move them efficiently toward engineering and development.

Why Rare Immune Clones Are the Real Therapeutic Signal

Most protective immune responses are driven by a small number of highly effective clonotypes. These include neutralizing antibodies derived from rare memory B cells, antigen-specific T cell clones that define protective immunity, and conserved cross-reactive responses that remain effective across pathogen variants. Collectively, these rare clones represent the biological basis for therapeutic antibody discovery, vaccine design, and immune-based drug development.

Traditional immune assays dilute these signals into noise. ELISAs, flow cytometry, and bulk RNA-seq capture response magnitude, but miss specificity, chain pairing, and clonal lineage. Immune repertoire sequencing enables researchers to identify, quantify, and track the exact clonotypes responsible for protection, transforming immune responses into actionable therapeutic leads.

The Complete Pipeline: From Discovery to Engineering

High-resolution bulk AIRR sequencing is the ideal first step for discovery, enabling scientists to map clonal diversity, identify expanded populations, and track immune dynamics across patient cohorts. At this scale, it is possible to detect rare clones against a background of millions, and to follow their trajectories longitudinally across infection, vaccination, or treatment. But discovery alone is not enough for therapeutic translation.

Moving a clonotype from a sequence list to a viable biologic candidate requires heavy/light or α/β−γ/δ chain pairing data, functional phenotype, and confirmed antigen specificity. Single-cell immune profiling closes that gap by connecting clonotype to function to mechanism. Together, bulk and single-cell AIRR analysis form a complete pipeline for immune-driven therapeutic development, from rare clone discovery to engineering-ready candidates.

Case Studies: Rare Clones as Therapeutic Assets

COVID-19: Mapping Durable and Broad Immunity

Immune repertoire analysis of SARS-CoV-2-infected and vaccinated individuals has revealed that both infection and vaccination generate broad, durable B cell and T cell memory that extends well beyond spike protein-specific responses.¹ Repertoire-level analysis enables identification of expanded memory clones associated with durable immunity, longitudinal tracking of immune persistence to inform booster strategies, and detection of broadly reactive responses relevant to emerging variants. This work demonstrates how immune repertoire sequencing can serve as a core tool for vaccine evaluation, durability assessment, and immune surveillance at scale.

Malaria: Isolating a Transmission-Blocking Monoclonal Antibody

In one of the most compelling examples of rare clone discovery in action, researchers mined antigen-specific B cell repertoires to identify a single rare monoclonal antibody (LMIV230-01) capable of blocking Plasmodium falciparum transmission across diverse parasite strains.²  By recovering paired heavy and light chains from rare memory B cells, linking clonal sequence features to functional neutralization, and characterizing a highly conserved discontinuous epitope on the Pfs230 gamete surface protein, the study provided a rational basis for both improved malaria vaccines and therapeutic antibody development. LMIV230-01 exemplifies how a single rare immune clone, correctly identified and characterized, can become a first-in-class biologic candidate.

iRepertoire’s Platform: From Discovery to Engineering

iRepertoire supports the full lifecycle of immune-driven therapeutic development through two complementary services.

• RepSeq+®: Ultra-sensitive bulk TCR and BCR RNA sequencing with seven-chain coverage for complete adaptive immune insight. Ideal for discovery at scale: mapping clonal diversity, detecting rare, clinically meaningful clonotypes across cohorts, and tracking immune dynamics longitudinally.
• iPair™: True single-cell capture of paired TCR and BCR chains with high pairing efficiency and without microfluidic dilution. Designed for antibody engineering, antigen specificity studies, and vaccine mechanism-of-action work.
• Advanced data analytics: Our data analysis platform transforms complex adaptive immune receptor repertoire data into clear, actionable insights that support every stage of research and therapeutic development. From essential, high-quality metrics for foundational repertoire characterization to deep analysis of clonal dynamics, somatic hypermutation, and cohort-level trends, each data analysis service is designed to expand biological understanding and accelerate decision-making.

Together, these technologies enable researchers to mine the immune repertoire for therapeutic assets and move them efficiently from rare clone discovery toward clinical development.

Conclusion

Infectious disease research is no longer limited to measuring immune responses. With advanced AIRR sequencing and data analysis, the adaptive immune system becomes a source of therapies, vaccines, and protective biologics. By combining high-sensitivity discovery with single-cell precision, iRepertoire helps biopharma teams transform immune responses into clinically actionable innovation.

Learn how RepSeq+® and iPair™ accelerate infectious disease and vaccine development.